Barr Pharmaceuticals, Inc. has confirmed that its subsidiary, Barr Laboratories, Inc., has initiated a challenge of the patents listed by Amgen Inc. in connection with its Sensipar Tablets (cincalcet hydrochloride), 30mg, 60mg and 90mg.
Source: http://www.news-medical.net/Pharmaceuticalnews.asp
Pharmaceutical News Feed